Introduction
============

Hepatocellular carcinoma (HCC) is the fifth most common cancer among men worldwide and the ninth in women, and a major cause of cancer-related mortality [@B1]. HCC is associated with a low 5-year survival rate and an increasing mortality rate [@B2], [@B3]. In Taiwan, HCC is the second major cause of cancer-associated deaths [@B4], [@B5].

Genetic variation plays a key role in HCC susceptibility and development of the disease. The majority of people who are exposed to the well-known infectious, lifestyle or environmental risk factors (i.e., hepatitis B or C virus infection, alcohol abuse or nonalcoholic fatty liver disease caused by obesity, type 2 diabetes and insulin resistance) do not develop HCC, which suggests that individual susceptibility modulates the tumor process [@B4]. Genotype distribution frequency data can be used to map single nucleotide polymorphism (SNP) diversity in a population and to examine the risk and development of specific diseases [@B6]. Emerging reports indicate an association between SNPs in certain genes and the susceptibility and clinicopathological status of HCC. For instance, individuals carrying specific interleukin-18 (*IL-18*) or high-mobility group box protein 1 (*HMGB1*) SNPs are at higher risk of HCC than wild-type carriers [@B7], [@B8].

AURKA, also known as aurora kinase A, is a mitotic serine/threonine kinase that plays a critical role in centrosome duplication and separation, spindle assembly, maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis [@B9]. Increased expression of AURKA may cause to chromosomal instability and transformation as well as centrosome amplification in mammalian cells [@B10]. AURKA overexpression has been observed in many human tumors [@B11]-[@B13], particularly in HCC [@B14]. It has also been reported that AURKA promotes the oncogenic effects of c-Myc, which is frequently amplified and overexpressed in many human cancers including HCC [@B15]. Genetic polymorphisms of *AURKA* have been indicated in several different cancer types (oral cancers, breast and ovarian cancers) [@B13], [@B16], [@B17]. It has been suggested that carriers of the *AURKA* 31Phe allele are less susceptible to hepatitis B virus (HBV)-related HCC when compared with noncarriers [@B18]. Scant research has examined the association between *AURKA* SNPs, HCC risk and prognosis. We therefore conducted a case-control study to evaluate the role of four *AURKA* SNPs on HCC susceptibility and clinicopathological features in a cohort of Chinese Han individuals.

Materials and Methods
=====================

Participants
------------

We enrolled 312 patients (cases) presenting with HCC to Chung Shan Medical University Hospital, Taiwan, between 2007 and 2015. A total of 624 anonymised healthy controls (HCs) were randomly selected from the Taiwan Biobank Project. All study participants were of Chinese Han ethnicity. HCC patients were staged according to the 2002 American Joint Committee on Cancer (AJCC) TNM staging system, which incorporates tumor morphology, number of lymph nodes affected, and metastases [@B19]. Before entering the study, each participant provided informed written consent and completed a structured questionnaire about sociodemographic status, cigarette and alcohol use. Liver cirrhosis was diagnosed by biopsy, appropriate sagittal CT or MRI scans, or biochemical evidence of liver parenchymal damage with endoscopic esophageal or gastric varices. The study was approved by the Institutional Review Board of Chung Shan Medical University Hospital prior to commencement.

Determination of genotypes
--------------------------

Total genomic DNA was isolated from whole blood specimens using QIAamp DNA blood mini kits (Qiagen, Valencia, CA), as per the manufacturer\'s instructions. This DNA was dissolved in TE buffer (10 mM Tris pH 7.8, 1 mM EDTA\] and stored at -20°C until it was subjected to quantitative polymerase chain reaction (PCR) analysis. Four *AURKA* SNPs (rs1047972, rs2273535, rs2064836, and rs6024836) with minor allele frequencies \>5% in the HapMap population were selected. Moreover, these SNPs have previously been found to associate with the development of cancer [@B13], [@B20], [@B21]. The *AURKA* SNPs were examined by the commercially available TaqMan SNP genotyping assay (Applied Biosystems, Warrington, UK), according to the manufacturer\'s protocols [@B22], [@B23].

Statistical analysis
--------------------

The genotype distribution of each SNP was analyzed for Hardy-Weinberg equilibrium and confirmed by Chi-square analysis. Demographic characteristics were compared between patients and controls using the Mann-Whitney U-test and Fisher\'s exact test. Associations between genotypes, HCC risk and clinicopathological characteristics were estimated using adjusted odds ratios (AORs) and 95% confidence intervals (CIs) obtained from age- and gender-adjusted multiple logistic regression models. A *p* value of \<0.05 was considered statistically significant. Data were analyzed using SAS statistical software (Version 9.1, 2005; SAS Institute Inc., Cary, NC).

Results
=======

Demographic characteristics did not differ significantly between the 312 patients with HCC and 624 cancer-free healthy controls (HCs) (Table [1](#T1){ref-type="table"}). Significantly fewer (*p* \< 0.001) controls compared with patients reported that they consumed alcohol, but cigarette smoking status did not differ between the two groups (*p* = 0.604) (Table [1](#T1){ref-type="table"}). Compared with controls, significantly higher proportions of HCC patients were positive for HBsAg (11.1% vs 43.9%; *p* \< 0.001) and anti-HCV antibodies (4.5% vs 47.4%; *p* \< 0.001) (Table [1](#T1){ref-type="table"}). 213 patients (68.3%) had stage I/II HCC and 99 (31.75%) had stage III/IV disease (Table [1](#T1){ref-type="table"}).

The distribution of the *AURKA* genotypes between the HCC patients and HCs is shown in Table [2](#T2){ref-type="table"}. In the HCs, all genotypic frequencies were in Hardy-Weinberg equilibrium (*p* \> 0.05). In both patients and controls, most of those with the rs1047972 SNP were homozygous for the C/C genotype, most of those with the rs2273535 SNP were homozygous for the T/T genotype, most of those with the rs2064836 SNP were homozygous for T/T, and most of those with the rs6024836 SNP were homozygous for A/A (Table [2](#T2){ref-type="table"}). After adjusting for potential confounders, subjects with T/T homozygotes of the *AURKA* rs1047972 polymorphism had a 2.678-fold (95% CI: 1.012-7.092; *p* \< 0.05) higher risk of developing HCC compared to those with C/C homozygotes. However, no significant differences in the incidences of HCC patients with the rs2273535, rs2064836, and rs6024836 polymorphisms compared to HCs.

Next, we compared the distributions of the clinical aspects and *AURKA* genotypes in HCC patients. Compared with patients with the T/T genotype, those with at least one polymorphic allele at the rs2273535 SNP (A/T or A/A genotype) were less prone to developing stage III/IV disease (*p* = 0.033), large tumors (*p* = 0.033) and Child-Pugh B or C grade (*p* = 0.033), but were more likely to develop liver cirrhosis (*p* = 0.045) (Table [3](#T3){ref-type="table"}). Moreover, carriers of the G/T+G/G genotype of rs2064863 had a lower risk than T/T carriers of developing large tumors (*p* = 0.047) and Child-Pugh grade B or C (*p* = 0.033), but were more likely to have HCV infection (*p* = 0.039) (Table [4](#T4){ref-type="table"}).

When we investigated associations between *AURKA* gene polymorphisms and serum levels of alpha-fetoprotein (AFP), aspartate transaminase (AST) and alanine transaminase (ALT) in HCC patients [@B24], we found significantly lower AFP levels in those carrying the rs1047972 T/C or T/T genotypes (*p* = 0.037; Table [5](#T5){ref-type="table"}).

Discussion
==========

AURKA, a centrosome-associated serine/threonine kinase, has demonstrated higher expression in various human cancers including colorectal cancer, breast cancer, head and neck squamous cell carcinoma, as well as HCC [@B11]-[@B13], [@B25]. It is postulated that this increase in expression might result in high chromosome instability in cancer and encourage susceptibility to malignant transformation [@B26], processes that may arise from the acquisition of the chromosome 20q amplicon, which promotes the adenoma to carcinoma progression [@B27]. In addition, overexpression of AURKA has been found to enhance tumor proliferation, differentiation, and metastasis [@B28]-[@B30]. AURKA also promotes cancer metastasis and cancer stem cells in HCC [@B31]. Inhibition of AURKA promotes autophagy and cell cycle arrest, and induces chemosensitivity in HCC [@B32]. These results suggest that knockdown AURKA might be a valuable therapeutic strategy for HCC. However, we dose not recruited the survival results of HCC patients. Future research could evaluate the association of AURKA polymorphisms with survival of HCC patients. In addition, it would be advisable to collect data on a larger number of patients for analysis of the functions of AURKA polymorphisms in HCC.

Since HCC is one of the most common and lethal tumors worldwide, preventing its occurrence and lowering its mortality rate is an important challenge. Infection with HBV or HCV, a history of liver cirrhosis, family history of HCC, and alcohol consumption are the dominant etiological factors for HCC in Taiwan [@B33]. In this study, there is no difference between the ratios of cigarette smokers/nonsmokers in controls (60.7:39.3) and HCC patients (59:41), whereas a higher proportion of HCC patients consumed alcohol (37.8%) compared with controls (13.9%). This suggests that alcohol consumption is a risk factor for HCC development. Chronic alcohol consumption promotes hepatobiliary tumors by increasing microRNA-122-controlled HIF-1α activity and stemness [@B34]. In a pig model, moderate alcohol consumption changed autophagy- and apoptosis-regulated pathways [@B35]. Exposure alcohol frequently changed genes at fragile sites, and promoted AURKA functioning. An increasing body of evidence shows that alcohol consumption is a risk factor for HCC [@B36], [@B37]. Our data is consistent with this finding, as those HCC patients who consumed alcohol were at higher risk of worsening disease.

The risk of breast cancer is high in individuals with the *AURKA* rs2273535 polymorphism [@B38], while the *AURKA* 91A (rs2273535) polymorphism is associated with a high risk of oral cancer [@B39]. In Caucasians, the *AURKA* rs1047972 polymorphism is associated with a decreased risk of breast cancer [@B40]. In this study, we did not find that the *AURKA* rs2273535 polymorphism was associated with HCC risk. However, our data does indicate that the *AURKA* rs1047972 polymorphism increases the risk of developing HCC. These findings suggest that different *AURKA* polymorphisms play different roles in cancer development.

This study found that HCC patients with the *AURKA* rs2273535 polymorphism had a lower risk of developing stage III/IV disease, large tumors, and Child-Pugh grade B or C. Similarly, the *AURKA* rs2064863 polymorphism was also associated with a lower risk of developing large tumors and Child-Pugh grade B or C. It is established that overexpression of the *AURKA* gene is implicated in the development of colorectal adenoma to colorectal cancer [@B26]. In addition, *AURKA* upregulation promotes high chromosome instability in cancerous tissue and induces increased susceptibility to tumor transformation [@B26]. However, more research is required to determine whether an association exists among advanced-stage disease, *AURKA* expression levels, and *AURKA* genotype, and clarification is needed in regard to the effects of the *AURKA* genotype on HCC risk.

In conclusion, the current study suggests a potentially clinically significant finding showing that several variants of the *AURKA* gene are associated with the clinical status and susceptibility of HCC. We found that individuals carrying the T/T allele of the *AURKA* SNP rs1047972 were at higher risk of HCC than wild-type (C/C) carriers. Genetic variations in the gene encoding *AURKA* may be a significant predictor of early HCC occurrence and a reliable biomarker for disease progression.
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###### 

Demographic characteristics of 624 healthy controls and 312 patients with HCC.

  Variable            Controls (N=624)   Patients (N=312)   *p* value
  ------------------- ------------------ ------------------ ----------------
  Age (yrs)           Mean ± S.D.        Mean ± S.D.        
                      59.53 ± 7.53       60.41 ± 9.44       *p* = 0.155
  Gender                                                    
  Male                452 (72.4%)        226 (72.4%)        
  Female              172 (27.6%)        86 (27.6%)         *p* = 1.000
  Cigarette smoking                                         
  No                  379 (60.7%)        184 (59.0%)        
  Yes                 245 (39.3%)        128 (41.0%)        *p* = 0.604
  Alcohol drinking                                          
  No                  537 (86.1%)        194 (62.2%)        
  Yes                 87 (13.9%)         118 (37.8%)        *p* \< 0.001\*
  HBsAg                                                     
  Negative            555 (88.9%)        175 (56.1%)        
  Positive            69 (11.1%)         137 (43.9%)        *p* \< 0.001\*
  Anti-HCV                                                  
  Negative            596 (95.5%)        164 (52.6%)        
  Positive            28 (4.5%)          148 (47.4%)        *p* \< 0.001\*
  Stage                                                     
  I+II                                   213 (68.3%)        
  III+IV                                 99 (31.7%)         
  Tumor T status                                            
  T1+T2                                  215 (68.9%)        
  T3+T4                                  97 (31.1%)         
  Lymph node status                                         
  N0                                     302 (96.8%)        
  N1+N2+N3                               10 (3.2%)          
  Metastasis                                                
  M0                                     297 (95.2%)        
  M1                                     15 (4.8%)          
  Child-Pugh grade                                          
  A                                      242 (77.6%)        
  B or C                                 70 (22.4%)         
  Liver cirrhosis                                           
  Negative                               52 (16.7%)         
  Positive                               260 (83.3%)        

Mann-Whitney U test or Fisher\'s exact test was used between healthy controls and patients with HCC. \* *p* value \< 0.05 as statistically significant.

###### 

Genotyping and allele frequency of *AURKA* single nucleotide polymorphisms (SNPs) in HCC patients and healthy controls.

  Variable        Controls (N=624 (%)   Patients (N=312 (%)   OR (95% CI)^a^
  --------------- --------------------- --------------------- ------------------------
  **rs1047972**                                               
  CC              485 (77.7%)           235 (75.3%)           1.000 (reference)
  TC              131 (21.0%)           67 (21.5%)            1.094 (0.751-1.594)
  TT              8 (1.3%)              10 (3.2%)             2.678 (1.012-7.092)^b^
  TC+TT           139 (22.3%)           77 (24.7%)            1.203 (0.841-1.720)
  **rs2273535**                                               
  TT              310 (49.7%)           152 (48.7%)           1.000 (reference)
  AT              257 (41.2%)           124 (39.8%)           1.004 (0.716-1.407)
  AA              57 (9.1%)             36 (11.5%)            1.263 (0.768-2.078)
  AT+AA           314 (50.3)            160 (51.3%)           1.061 (0.775-1.451)
  **rs2064863**                                               
  TT              444 (71.1%)           217 (69.6%)           1.000 (reference)
  GT              162 (26.0%)           88 (28.2%)            1.143 (0.804-1.624)
  GG              18 (2.9%)             7 (2.2%)              0.600 (0.221-1.628)
  GT+GG           180 (28.9%)           95 (30.4%)            1.073 (0.764-1.506)
  **rs6024836**                                               
  AA              284 (45.5%)           147 (47.1%)           1.000 (reference)
  AG              268 (43.0%)           130 (41.7%)           1.052 (0.755-1.466)
  GG              72 (11.5%)            35 (11.2%)            0.949 (0.569-1.582)
  AG+GG           340 (54.5%)           165 (52.9%)           1.029 (0.752-1.407)

^a^ adjusted for the effects of age and gender.

^b^ *p* = 0.047.

###### 

Odds ratios (ORs) and 95% confidence intervals (CIs) of clinical status and *AURKA* rs2273535 genotype frequencies in 312 HCC patients.

  Variable                Genotypic frequencies                                         
  ----------------------- ----------------------- --------------- --------------------- -------------------
                          TT (N=152)              AT+AA (N=160)   OR (95% CI)           *p* value
  Clinical Stage                                                                        
  Stage I/II              95 (62.5%)              118 (73.7%)     1.00                  ***P*=0.033^\*^**
  Stage III/IV            57 (37.5%)              42 (26.3%)      0.593 (0.367-0.960)   
  Tumor size                                                                            
  ≤ T2                    96 (63.2%)              119 (74.4%)     1.00                  ***P*=0.033^\*^**
  \> T2                   56 (36.8%)              41 (25.6%)      0.591 (0.364-0.959)   
  Lymph node metastasis                                                                 
  No                      146 (96.1%)             156 (97.5%)     1.00                  *P*=0.472
  Yes                     6 (3.9%)                4 (2.5%)        0.624 (0.173-2.256)   
  Distant metastasis                                                                    
  No                      144 (94.7%)             153 (95.6%)     1.00                  *P***=**0.714
  Yes                     8 (5.3%)                7 (4.4%)        0.824 (0.291-2.329)   
  Vascular invasion                                                                     
  No                      124 (81.6%)             134 (83.8%)     1.00                  *P*=0.613
  Yes                     28 (18.4%)              26 (16.2%)      0.859 (0.478-1.546)   
  Child-Pugh grade                                                                      
  A                       110 (72.4%)             132 (82.5%)     1.00                  ***P=*0.033^\*^**
  B or C                  42 (27.6%)              28 (17.5%)      0.556 (0.323-0.954)   
  HBsAg                                                                                 
  Negative                79 (52.0%)              96 (60.0%)      1.00                  *P*=0.496
  Positive                73 (48.0%)              64 (40.0%)      0.898 (0.659-1.224)   
  Anti-HCV                                                                              
  Negative                86 (56.6%)              78 (48.8%)      1.00                  *P*=0.099
  Positive                66 (43.4%)              82 (51.2%)      1.320 (0.949-1.836)   
  Liver cirrhosis                                                                       
  Negative                32 (21.1%)              20 (12.5%)      1.00                  ***P*=0.045^\*^**
  Positive                120 (78.9%)             140 (87.5%)     1.867 (1.015-3.434)   

The ORs with analyzed by their 95% CIs were estimated by logistic regression models.

\> T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)

\* *p* value \< 0.05 as statistically significant.

###### 

Odds ratio (OR) and 95% confidence interval (CI) of clinical status and *AURKA* rs2064863 genotypic frequencies in 312 HCC patients.

  Variable                Genotypic frequencies                                        
  ----------------------- ----------------------- -------------- --------------------- -------------------
                          TT (N=217)              GT+GG (N=95)   OR (95% CI)           *p* value
  Clinical Stage                                                                       
  Stage I/II              141 (65.0%)             72 (75.8%)     1.00                  *P*=0.061
  Stage III/IV            76 (35.0%)              23 (24.2%)     0.593 (0.343-1.023)   
  Tumor size                                                                           
  ≤ T2                    142 (65.4%)             73 (76.8%)     1.00                  ***P*=0.047^\*^**
  \> T2                   75 (34.6%)              22 (23.2%)     0.571 (0.328-0.992)   
  Lymph node metastasis                                                                
  No                      209 (96.3%)             93 (97.9%)     1.00                  *P*=0.471
  Yes                     8 (3.7%)                2 (2.1%)       0.562 (0.117-2.697)   
  Distant metastasis                                                                   
  No                      205 (94.5%)             92 (96.8%)     1.00                  *P*=0.374
  Yes                     12 (5.5%)               3 (3.2%)       0.557 (0.154-2.021)   
  Vascular invasion                                                                    
  No                      176 (81.1%)             82 (86.3%)     1.00                  *P*=0.265
  Yes                     41 (18.9%)              13 (13.7%)     0.681 (0.346-1.339)   
  Child-Pugh grade                                                                     
  A                       161 (74.2%)             81 (85.3%)     1.00                  ***P*=0.033^\*^**
  B or C                  56 (25.8%)              14 (14.7%)     0.497 (0.261-0.946)   
  HBsAg                                                                                
  Negative                117 (53.9%)             58 (61.1%)     1.00                  *P*=0.193
  Positive                100 (46.1%)             37 (38.9%)     0.793 (0.559-1.125)   
  Anti-HCV                                                                             
  Negative                119 (54.8%)             45 (47.4%)     1.00                  ***P*=0.039^\*^**
  Positive                98 (45.2%)              50 (52.6%)     1.441 (1.019-2.038)   
  Liver cirrhosis                                                                      
  Negative                38 (17.5%)              14 (14.7%)     1.00                  *P*=0.546
  Positive                179 (82.5%)             81 (85.3%)     1.228 (0.631-2.392)   

The ORs with analyzed by their 95% CIs were estimated by logistic regression models.

\> T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)

\* *p* value \< 0.05 as statistically significant.

###### 

Association of *AURKA* genotype frequencies with laboratory findings in liver tests from HCC patients.

  Characteristic   α-Fetoprotein ^a^ (ng/mL)   AST (IU/L)     ALT (IU/L)     AST/ALT ratio
  ---------------- --------------------------- -------------- -------------- ---------------
  **rs1047972**                                                              
  CC               1226.8 ± 365.6              58.61 ± 5.88   54.82 ± 5.48   1.23 ± 0.03
  TC+TT            396.8 ± 153.0               47.51 ± 3.91   49.10 ± 4.84   1.19 ± 0.04
  *p* value        **0.037\***                 0.116          0.434          0.470
  **rs2273535**                                                              
  TT               1480.6 ± 523.4              63.39 ± 8.66   57.91 ± 8.00   1.23 ± 0.03
  AT+AA            601.2 ± 230.3               48.89 ± 3.41   49.20 ± 3.63   1.21 ± 0.05
  *p* value        0.125                       0.120          0.322          0.654
  **rs2064863**                                                              
  TT               1144.4 ± 369.3              57.82 ± 6.18   54.39 ± 5.77   1.22 ± 0.02
  GT+GG            772.8 ± 380.2               51.79 ± 5.12   51.36 ± 5.25   1.21 ± 0.07
  *p* value        0.483                       0.453          0.698          0.889
  **rs6024836**                                                              
  AA               1365.9 ± 493.4              65.00 ± 9.21   59.93 ± 8.49   1.26 ± 0.05
  AG+GG            753.0 ± 314.7               48.41 ± 3.35   48.01 ± 3.57   1.19 ± 0.02
  *p* value        0.295                       0.091          0.196          0.193

Mann-Whitney U test was used between two groups.

^a^ Mean ± S.E.

\* *p* value \< 0.05 as statistically significant.
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